

# ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

## A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

**Trial Status**  
Recruiting

**Trial Runs In**  
5 Countries

**Trial Identifier**  
NCT06497556 2024-510908-37-00  
BO45217

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT06497556 2024-510908-37-00 BO45217**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---